Table 1.
Reference | Country | Substance | Cost categories | Cost measurement | Productivity losses measurement |
---|---|---|---|---|---|
Ruff et al. (21) | Germany | Tobacco | Direct costs/indirect costs | Prevalence-based | Human capital method |
Garcia-Altes et al. (27) | Spain | Illicit drugs | Direct costs/indirect costs | Prevalence-based | Human capital method |
Varney and Guest (26) | Scotland | Alcohol | Direct costs/indirect costs | Prevalence-based | Human capital method |
Fenoglio et al. (25) | France | Alcohol, tobacco, and illicit drugs | Direct costs/indirect costs | Prevalence-based | Human capital method |
Rasmussen et al. (24) | Denmark | Tobacco | Direct costs/indirect costs | Incidence-based | Human capital method |
Neubauer et al. (20) | Germany | Tobacco | Direct costs/indirect costs | Prevalence-based | Human capital method |
Konnopka and König (18) | Germany | Alcohol | Direct costs/indirect costs | Prevalence-based | Human capital method |
Rehm et al. (23) | Canada | Alcohol, tobacco, and illicit drugs | Direct costs/indirect costs | Prevalence-based | Human capital method |
Jarl et al. (28) | Sweden | Alcohol | Direct costs/indirect costs/intangible costs | Prevalence-based | Human capital method |
Konnopka et al. (33) | Germany | Alcohol | Direct costs/indirect costs/intangible costs | Prevalence-based | Human capital method |
Hansen et al. (29) | US | Psychoactive pharmaceuticals | Direct costs/indirect costs | Prevalence-based | Human capital method |
Wacker et al. (22) | Germany | Tobacco | Direct costs/indirect costs | Prevalence-based | Human capital method |